medigraphic.com
ISSN 0301-696X (Print)
Órgano de difusión del Servicio de Sanidad Militar y del Colegio Nacional de Médicos Militares

2019, Number 1

Next >>

Rev Sanid Milit Mex 2019; 73 (1)

Volumetric analysis of brain, by magnetic resonance imaging, in the monitoring of patients with multiple sclerosis and its correlation with disability

Organista‑Mondragón N, Marrufo‑Meléndez Ó,  Rivas‑Alonso V, Ríos‑Castañeda C

Language: Spanish
References: 17
Page: 5-10
PDF size: 270.42 Kb.


ABSTRACT

Introduction: Multiple sclerosis (MS) is the main cause of non-traumatic disability in young people, it is a neurodegenerative disease. In Mexico it afects 11-20 per 100,000 population; 80-85% presents with the Relapsing- Remitting Multiple Sclerosis (RRMS); brain volumen loss is increased in afectted people compared with general population. Objective: Obtain brain volumetric magnetic resonance imaging (MRI) of the patients with RRMS in the two year follow-up, describe their brain volumen loss and its correlaction with the expanded disability status scale (EDSS). Material and methods: 15 patients with a diagnosis of RRMS were studied at baseline and two years later brain MRI, obtaining brain volumetry of 29 structures using FreeSurfer software. Results: There were statistically significant difference between the subjects over time in the total cerebral volumetry (p = 0.051). Decreased volumen of the left hippocampus and right putamen. Moderate correlation between differences of the left globus pallidus volumetries and two-year disability scales. Conclusions: The decrease in subcortical gray matter (globus pallidus) in two-years follow-up could be a disability predictor. Structures with greatest volumen loss: total brain volumen, left hippocampus and right putamen, could be considered markers of neurodegeneration in the MS process.


REFERENCES

  1. Calabresi PA. Diagnosis and management of multiple sclerosis. Am Fam Physician. 2004; 70: 1935-1944.

  2. Compston A, Coles A. Multiple sclerosis. Lancet. 2002; 359 (9313): 1221-1231.

  3. Wilkins A, Majed H, Layfield R, Compston A, Chandran S. Oligodendrocytes promote neuronal survival and axonal length by distinct intracellular mechanisms: a novel role for oligodendrocyte-derived glial cell line-derived neurotrophic factor. J Neurosci. 2003; 23: 4967-4974.

  4. Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Brück W. Acute axonal injury in multiple sclerosis: correlation with demyelination and inflammation. Brain. 2000; 123: 1174-1183.

  5. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33: 1444-1452.

  6. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005; 58 (6): 840-846.

  7. Rovira A, León A. MR in the diagnosis and monitoring of multiple sclerosis: an overview. European Journal of Radiology. 2008; 67 (3): 409-414.

  8. Miller DH, Barkhof F, Frank JA et al. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain. 2002; 125: 1676-1695.

  9. Raz N, Rodrigue KM. Differential aging of the brain: patterns, cognitive correlates and modifiers. Neurosci Biobehav Rev. 2006; 30: 730-748. doi: 10.1016/j.neubiorev.2006.07.001.

  10. Cotton F, Weiner H, Jolesz F, Guttmann C. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology. 2003; 60: 640-646.

  11. Dale AM, Fischl B et al. Cortical surface-based analysis: segmentation and surface reconstruction. Neuroimage. 1999; 9 (2): 179-194.

  12. Confavreux C, Vukusic S. The clinical epidemiology of multiple sclerosis. Neuroimaging 
Clinics of North America. 2008; 18 (4): 589-622, IX-X.

  13. Marrie RA. Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol. 2004; 3: 709-718.

  14. Onu M, Roceanu A, Ferastraoaru V et al. Gray matter changes in demyelinating disease: correlations whit clinical scores. A Journal of Clinical Medicine. 2015; 10 (4): 319-324.

  15. Jacobsen C, Hagemeier J, Myhr K et al. Brain atrophy and disability progression in multiples sclerosis patients: a 10 year follow-up study. Neurol Neurosurg Psychiatry. 2014; 85: 1-7.

  16. Zivadinov R, Bergsland N, Dolezal O et al. Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years. AJNR Am J Neuroradiol. 2013; 34: 1931-1939.

  17. Sastre-Garriga P, Rovira A. Brain atrophy in multiple sclerosis. Neuroimaging Clin N Am. 2017; 27: 289-300.




2020     |     www.medigraphic.com